Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes

Molecular Psychiatry

Volumn 13, Issue 7, 2008, Pages 697-708

  Xiao, L ^a,f   Xu, H ^b   Zhang, Y ^a   Wei, Z ^a   He, J ^a   Jiang, W ^a   Li, X ^c   Dyck, L E ^a   Devon, R M ^d   Deng, Y ^e   Li, X M ^a,g  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e BEIJING INSTITUTE OF TECHNOLOGY   (China)

^f THIRD MILITARY MEDICAL UNIVERSITY   (China)

^g UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antipsychotics; Differentiation; Myelin breakdown; Neural progenitors; Oligodendrocytes; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CUPRIZONE; GROWTH FACTOR; MYELIN; MYELIN BASIC PROTEIN; NEUROTOXIN; QUETIAPINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DEMYELINATION; DRUG MECHANISM; EMBRYO; FETUS; MEMORY DISORDER; MOUSE; MYELINATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SCHIZOPHRENIA; STEM CELL; WORKING MEMORY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BROMODEOXYURIDINE; CELL AGGREGATION; CELLS, CULTURED; CEREBRAL CORTEX; DIBENZOTHIAZEPINES; HUMANS; MYELIN SHEATH; OLIGODENDROGLIA; POSTMORTEM CHANGES; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; TETRAZOLIUM SALTS;

EID: 45549101680     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002064     Document Type: Article

References (57)

1. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669.
2. Bloom FE. Advancing a neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 1993; 50: 224-227.
3. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? BMJ 1987; 296: 681-682.
4. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002; 25: 409-432.
5. Bartzokis G, Beckson M, Lu PH, Nuechterlein K, Edwards N, Mintz J. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58: 461-465.
6. Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F. Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry 1992; 49: 921-926.
7. Buchanan RW, Vladar K, Barta PE, Pearlson GD. Structural evaluation of the prefrontal cortex in schizophrenia. Am J Psychiatry 1998; 155: 1049-1055.
8. Cannon TD, van Erp TG, Huttunen M, Lonnqvist J, Salonen O, Valanne L et al. Regional gray matter, white matter, and cerebrospinal fluid distributions in schizophrenic patients, their siblings, and controls. Arch Gen Psychiatry 1998; 55: 1084-1091.
9. Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 2000; 57: 471-480.
10. Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RF, Maier SE et al. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. NeuroImage 2005; 26: 1109-1118.
11. Schlosser RG, Nenadic I, Wagner G, Gullmar D, von Consbruch K, Kohler S et al. White matter abnormalities and brain activation in schizophrenia: a combined DTI and fMRI study. Schizophr Res 2007; 89: 1-11.
12. Minami T, Nobuhara K, Okugawa G, Takase K, Yoshida T, Sawada S et al. Diffusion tensor magnetic resonance imaging of disruption of regional white matter in schizophrenia. Neuropsychobiology 2003; 47: 141-145.
13. Hoptman MJ, Ardekani BA, Butler PD, Nierenberg J, Javitt DC, Lim KO. DTI and impulsivity in schizophrenia: a first voxelwise correlational analysis. Neuroreport 2004; 15: 2467-2470.
14. Ardekani BA, Nierenberg J, Hoptman MJ, Javitt DC, Lim KO. MRI study of white matter diffusion anisotropy in schizophrenia. Neuroreport 2003; 14: 2025-2029.
15. Walterfang M, Wood SJ, Velakoulis D, Copolov D, Pantelis C. Diseases of white matter and schizophrenia-like psychosis. Aust NZ J Psychiatry 2005; 39: 746-756.
16. Elvidge A, Reed G. Biopsy studies of cerebral pathologic changes in schizophrenia and manic-depressive psychosis. Arch Neurol Psychiatry 1938; 40: 227-268.
17. Peirce TR, Bray NJ, Williams NM, Norton N, Moskvina V, Preece A et al. Convergent evidence for 2′, 3′-cyclic nucleotide 3′-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch Gen Psychiatry 2006; 63: 18-24.
18. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751.
19. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2005; 362: 798-805.
20. Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res 2005; 79: 157-173.
21. Aberg K, Saetre P, Jareborg N, Jazin E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc Natl Acad Sci USA 2006; 103: 7482-7487.
22. Gravel M, Peterson J, Yong VW, Kottis V, Trapp B, Braun PE. Overexpression of 2′,3′-cyclic nucleotide 3′-phosphodiesterase in transgenic mice alters oligodendrocyte development and produces aberrant myelination. Mol Cell Neurosci 1996; 7: 453-466.
23. Schachner M, Bartsch U. Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia 2000; 29: 154-165.
24. Yakovlev PI, Lecours AR. The myelogenetic cycles of regional maturation of the brain. In: Minkowski A (ed). Regional Development of the Brain in Early Life. Blackwell: Boston, 1967,pp 3-70.
25. Benes FM, Turtle M, Khan Y, Farol P. Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Arch Gen Psychiatry 1994; 51: 477-484.
26. Bartzokis G, Nuechterlein KH, Lu PH, Gitlin M, Rogers S, Mintz J. Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol Psychiatry 2003; 53: 412-421.
27. Andreone N, Tansella M, Cerini R, Rambaldelli G, Versace A, Marrella G et al. Cerebral atrophy and white matter disruption in chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007; 257: 3-11.
28. Narayan S, Kass KE, Thomas EA. Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. J Neurosci Res 2007; 85: 757-765.
29. Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001; 11: 107-116.
30. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255: 1707-1710.
31. Honegger P, Lenoir D, Favrod P. Growth and differentiation of aggregating fetal brain cells in a serum-free defined medium. Nature 1979; 282: 305-308.
32. Devon RM. Comparison of oligodendrocytes grown in neocortex and spinal cord aggregate cultures. Brain Res 1987; 429: 289-294.
33. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. Identification of a novel inhibitor of mitogen-activated protein kinase. J Biol Chem 1998; 273: 18623-18632.
34. Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJM. Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol 2003; 13: 329-339.
35. Councill JH, Tucker ES, Haskell GT, Maynard TM, Meechan DW, Hamer RM et al. Limited influence of olanzapine on adult forebrain neural precursors invitro. Neuroscience 2006; 140: 111-122.
36. Hsieh J, Aimone JB, Kaspar BK, Kuwabara T, Nakashima K, Gage FH. IGF-I instructs multipotent adult neural progenitor cells to become oligodendrocytes. J Cell Biol 2004; 164: 111-122.
37. Palacios N, Sanchez-Franco F, Fernandez M, Sanchez I, Cacicedo L. Intracellular events mediating insulin-like growth factor I-induced oligodendrocyte development: modulation by cyclic AMP. J Neurochem 2005; 95: 1091-1107.
38. Baumann N, Pham-dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001; 81: 871-927.
39. Diemel LT, Jackson SJ, Cuzner ML. Role for TGF-β1, FGF-2 and PDGF-AA in a myelination of CNS aggregate cultures enriched with macrophages. J Neurosci Res 2003; 74: 858-867.
40. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 2005; 5: 298-304.
41. Ferno J, Skrede S, Vik-Mo AO, Havik B, Steen VM. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 2006; 7: 69-79.
42. Glahn DC, Therman S, Manninen M, Huttunen M, Kaprio J, Lonnqvist J et al. Spatial working memory as an endophenotype for schizophrenia. Biol Psychiatry 2003; 53: 624-626.
43. Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN et al. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia. Pharmacol Biochem Behav 2005; 82: 361-372.
44. Gustafsson B, Christensson E. Amperozide - a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour. Pharmacol Toxicol 1990; 66(Suppl 1): 12-17.
45. Ogren SO, Hall H, Kohler C, Magnusson O, Lindbom LO, Angeby K et al. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 1984; 102: 459-474.
46. Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol 2004; 19: 559-563.
47. Sax KW, Strakowski SM, Keck Jr PE. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res 1998; 33: 151-155.
48. Hof PR, Haroutunian V, Friedrich Jr VL, Byne W, Buitron C, Perl DP et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003; 53: 1075-1085.
49. Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and trans-differentiations. Annu Rev Cell Dev Biol 2001; 17: 387-403.
50. Morrison RS, Kornblum HI, Leslie FM, Bradshaw RA. Trophic stimulation of cultured neurons from neonatal rat brain by epidermal growth factor. Science 1987; 238: 72-75.
51. Zheng W, Nowakowski RS, Vaccarino FM. Fibroblast growth factor 2 is required for maintaining the neural stem cell pool in the mouse brain subventricular zone. Dev Neurosci 2004; 26: 181-196.
52. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006; 11: 514-522.
53. Fumagalli F, Molteni R, Bedogni F, Gennarelli M, Perez J, Racagni G et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 2004; 15: 2109-2112.
54. Riva MA, Molteni R, Tascedda F, Massironi A, Racagni G. Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine. Neuropharmacology 1999; 38: 1075-1082.
55. Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy: insights into the neurobiology of psychosis. Arch Neurol 1992; 49: 401-406.
56. Eliez S, Antonarakis SE, Morris MA, Dahoun SP, Reiss AL. Parental origin of the deletion 22q11.2 and brain development in velofacial syndrome. Arch Gen Psychiatry 2001; 58: 64-68.
57. Eliez S, Schmitt JE, White CD, Reiss AL. Children and adolescents with velocardiofacial syndrome: a volumetric MRI study. Am J Psychiatry 2000; 157: 409-415.